ST. LOUIS– A new modeling study published in Clinical Gastroenterology and Hepatology supports the clinical value of Geneoscopy’s ColoSense®, the only FDA-approved multitarget stool RNA (mt-sRNA) test for colorectal cancer (CRC) screening. The study, which simulates real-world conditions, found that ColoSense offers significant mortality reduction and cost-effectiveness among noninvasive screening methods for adults aged 45 and older.
The research, titled “Cost-effectiveness of novel noninvasive screening tests for colorectal neoplasia,” used a 10-year Markov model to evaluate five CRC screening strategies: mt-sRNA (ColoSense), two multitarget stool DNA (mt-sDNA) tests, a blood-based test, and the fecal immunochemical test (FIT). The study accounted for typical screening adherence levels, which are often lower in practice than in controlled clinical trials.
At a real-world adherence rate of 60 percent, ColoSense reduced CRC deaths by 14 percent compared to FIT, by 19 and 23 percent compared to the two mt-sDNA tests, and by 86 percent compared to the blood-based test. While FIT remained the most cost-effective option overall, ColoSense was the most cost-effective among molecular tests across all adherence scenarios.
“These findings highlight the importance of using models that reflect the actual populations being screened,” said Dr. Erica Barnell, Chief Science and Medical Officer at Geneoscopy and co-author of the study. “ColoSense was designed to perform reliably across diverse patient groups, including younger adults who are frequently underrepresented in clinical trials.”
Unlike many assays that rely on methylation-based biomarkers—known to have lower sensitivity in younger patients—ColoSense uses RNA-based technology, which may offer more consistent performance across age groups. The study adjusted test sensitivity data to align with the demographics of the general screening population, enhancing its relevance to clinical practice.
ColoSense’s growing clinical profile is further supported by its inclusion in the 2025 update of the National Comprehensive Cancer Network (NCCN) screening guidelines. The test represents a noninvasive, accessible alternative to colonoscopy and may help address screening disparities by encouraging greater participation among populations less likely to undergo invasive procedures.
Geneoscopy’s work emphasizes the need for CRC screening tools that are both accurate and practical. The company views the publication of this latest study as validation of its approach to expanding access to early detection methods that can improve outcomes and reduce the burden of colorectal cancer.
